Stereotaxis (STXS) AI Stock Analysis

• Market Cap: $247.71M
• Dividend Yield: N/A
• Average Volume (3M): 524.71K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.68
• Revenue Growth: 19.61%
• EPS Growth: -3.42%
• Country: US
• Employees: 139
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Instruments & Supplies
• EPS (TTM): -0.07
• Shares Outstanding: 91,071,480
• 10 Day Avg. Volume: 429,315
• 30 Day Avg. Volume: 524,706
• PEG Ratio: -0.73
• Price to Book (P/B): 16.99
• Price to Sales (P/S): 7.22
• P/FCF Ratio: -22.77
• Enterprise Value/Market Cap: 0.77
• Enterprise Value/Revenue: 6.33
• Enterprise Value/Gross Profit: 11.94
• Enterprise Value/Ebitda: -8.58
• 1Y Price Target: $4.33
• Price Target Upside: 59.19% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 3
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 58 Neutral
• Price Target: $2.50 ▼(-8.09% Downside)

Stereotaxis' stock score is primarily influenced by its financial performance, which shows revenue consistency but profitability challenges. The positive sentiment from the earnings call, including FDA approval and revenue growth projections, provides a boost. However, technical indicators suggest bearish momentum, and valuation metrics are unfavorable due to ongoing losses.

Positive Factors

FDA Approval of GenesisX

FDA approval for GenesisX removes structural barriers, enhancing market opportunities and expected to drive future revenue growth.

Recurring Revenue Growth

Strong growth in recurring revenue indicates increasing adoption of products, providing a stable revenue base and supporting long-term financial health.

Product Pipeline and Innovation

Successful launch of new products like MAGiC Sweep demonstrates innovation and potential for increased market share and revenue.

Negative Factors

Profitability Challenges

Continued operating and net losses highlight the need for improved cost management and profitability to ensure long-term sustainability.

Negative Cash Flow

Persistent negative cash flow indicates challenges in cash generation, necessitating strategic cash management to support operations.

Pending U.S. Approval for MAGiC

Pending U.S. approval for MAGiC catheter could delay market penetration and revenue growth, impacting competitive positioning.

Stereotaxis Business Overview & Revenue Model

Company Description

Stereotaxis, Inc. is a leader in the field of robotic-assisted cardiac surgery and electrophysiology. Based in St. Louis, Missouri, the company develops advanced robotic systems and software for the treatment of complex heart conditions. Its flagship product, the Niobe® Robotic Magnetic Navigation System, enables the precise navigation of catheters in the heart, improving the accuracy and safety of procedures such as ablation for arrhythmias. Stereotaxis operates primarily in the medical technology sector and focuses on enhancing patient outcomes through innovation in cardiac care.

How the Company Makes Money

Stereotaxis generates revenue primarily through the sale of its robotic systems, disposable catheters, and software solutions. The company earns money from the initial sale of its Niobe® systems to hospitals and medical institutions, which is often accompanied by service agreements and maintenance contracts that provide ongoing revenue. Additionally, Stereotaxis benefits from recurring revenue through the sale of disposable catheters used in procedures performed with its robotic systems. Partnerships with hospitals and medical centers, as well as collaborations with other medical technology firms, also contribute to its earnings by expanding its customer base and enhancing its product offerings.

Stereotaxis Financial Statement Overview

Summary

Stereotaxis shows consistent revenue but struggles with profitability due to high operational costs, resulting in negative net income. The balance sheet indicates balanced leverage but limited equity, while cash flow constraints highlight the need for improved cash management.

Income Statement

Stereotaxis has shown marginal revenue growth over the years but faces challenges in profitability. The gross profit margin remains robust at around 54.2% for 2024, but the company continues to operate at a net loss, with a net profit margin of -94.2% in 2024. This indicates high operational costs relative to revenue, leading to negative EBIT and EBITDA margins, which suggest a need for cost management and strategic improvements.

Balance Sheet

The debt-to-equity ratio for 2024 stands at approximately 0.99, showing a balanced leverage profile. However, the equity ratio is relatively low at 13.0%, indicating limited asset backing by equity. The company’s return on equity is negative due to sustained losses, highlighting potential financial stability concerns.

Cash Flow

Free cash flow has seen a slight improvement but remains negative, reflecting cash outflow challenges. The operating cash flow to net income ratio is unfavorable due to negative cash flows, indicating issues in converting revenue into cash. The free cash flow to net income ratio also highlights cash generation difficulties, requiring strategic cash flow management.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	30.07M	26.92M	26.77M	28.15M	35.02M	26.63M
Gross Profit	15.96M	14.59M	14.86M	18.47M	23.23M	18.97M
EBITDA	-22.20M	-23.77M	-21.24M	-18.35M	-12.78M	-6.59M
Net Income	-23.63M	-24.05M	-20.71M	-18.29M	-10.72M	-6.65M
Balance Sheet
Total Assets	45.59M	46.72M	41.91M	53.41M	60.98M	55.46M
Cash, Cash Equivalents and Short-Term Investments	10.51M	12.22M	19.82M	28.43M	38.74M	43.94M
Total Debt	5.58M	6.01M	5.49M	5.86M	6.11M	4.45M
Total Liabilities	34.05M	35.29M	19.99M	21.48M	21.56M	15.23M
Stockholders Equity	11.53M	11.43M	21.92M	31.93M	39.42M	40.23M
Cash Flow
Free Cash Flow	-4.27M	-8.53M	-9.51M	-10.79M	-4.34M	-3.58M
Operating Cash Flow	-4.25M	-8.50M	-9.14M	-8.41M	-2.95M	-3.51M
Investing Cash Flow	-25.00K	74.00K	19.77M	-22.09M	-1.40M	-70.90K
Financing Cash Flow	225.00K	297.00K	81.00K	220.00K	547.00K	17.34M

Stereotaxis Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 2.72
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For STXS, the sentiment is Negative. The current price of 2.72 is above the 20-day moving average (MA) of 2.65, below the 50-day MA of 2.88, and above the 200-day MA of 2.37, indicating a bearish trend. The MACD of -0.21 indicates Positive momentum. The RSI at 33.29 is Neutral, neither overbought nor oversold. The STOCH value of 20.83 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for STXS.

Stereotaxis Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
MMSI	78 Outperform	$4.96B	42.83	8.30%	―	11.49%	-2.89%
LMAT	75 Outperform	$1.95B	41.90	15.02%	0.92%	13.07%	27.98%
ATRC	65 Neutral	$1.70B	―	-6.11%	―	15.80%	26.94%
STXS	58 Neutral	$247.71M	―	-170.24%	―	19.61%	-3.42%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
STAA	49 Neutral	$1.32B	―	-24.65%	―	-32.42%	-540.37%
MLSS	41 Neutral	$29.73M	-4.35	-136.47%	―	0.59%	-39.76%

Stereotaxis Corporate Events

Stereotaxis Earnings Call: Growth Amid Challenges

Stereotaxis’ recent earnings call paints a picture of both optimism and caution. The company is celebrating significant milestones, such as the FDA approval for GenesisX and robust growth in recurring revenue. However, challenges remain, including financial losses and pending regulatory approvals.

Stereotaxis Advances in Surgical Robotics with Strong Q3

Stereotaxis, a leader in surgical robotics for minimally invasive endovascular interventions, continues to advance its innovative technology portfolio, aiming to enhance patient care and operating room efficiency. In its third-quarter earnings report for 2025, Stereotaxis highlighted significant commercial progress, including the sale of two Genesis robotic systems to European hospitals and the successful launch of new products like MAGiC Sweep, which generated over $300,000 in revenue shortly after FDA clearance. The company reported total revenue of $7.5 million, with a gross margin of 55%, and noted a decrease in adjusted operating expenses compared to the previous year. Despite an operating loss of $6.6 million, Stereotaxis maintains a strong cash position with $10.5 million in cash and no debt. Looking ahead, Stereotaxis anticipates fourth-quarter revenue to exceed $9 million, driven by continued growth in both system and recurring revenue, supporting its goal of achieving over 20% annual revenue growth for 2025.

Stereotaxis Enters $50M Sales Agreement with Roth Capital

On August 29, 2025, Stereotaxis, Inc. entered into a Sales Agreement with Roth Capital Partners, LLC to sell up to $50 million in common stock. The proceeds are intended for working capital, research and development, and accelerating the commercialization of their innovation pipeline. This agreement allows Stereotaxis to offer shares through Roth Capital as sales agent or principal, with sales made as at-the-market offerings or through privately negotiated transactions. The arrangement provides flexibility in raising capital based on market conditions and the company’s needs, potentially impacting its operational capabilities and market positioning.

The most recent analyst rating on (STXS) stock is a Hold with a $3.00 price target. To see the full list of analyst forecasts on Stereotaxis stock, see the STXS Stock Forecast page.